NCT03490240 (BIPAMS) is a NA clinical trial of BIPAMS in Multiple Sclerosis, sponsored by University of Alabama at Birmingham.

Who is sponsoring NCT03490240?

NCT03490240 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT03490240?

Interventions in NCT03490240: BIPAMS, WELLMS.

What condition does NCT03490240 study?

NCT03490240 studies Multiple Sclerosis.

Is NCT03490240 still recruiting?

NCT03490240 is currently active, enrolled. Last updated 22 December 2025.

Last reviewed 2025-12-22 · How we verify

NCT03490240: BIPAMS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Project BIPAMS: Behavioral Intervention for Physical Activity in Multiple Sclerosis

Active, enrolled NA Last updated 22 December 2025

What this trial tests

NA trial testing BIPAMS in Multiple Sclerosis in 280 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 March 2018

Primary endpoint
1 March 2023

31 December 2026

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	280
Start date	1 March 2018
Primary completion	1 March 2023
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

BIPAMS
WELLMS

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

University of Alabama at Birmingham

Who can join

Adults 18 to 64, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized controlled trial will examine the effect of a 6-month behavioral intervention, based on social cognitive theory and delivered through the Internet, for increasing physical activity and secondarily improving mobility, cognition, symptoms and quality of life in persons with MS. The investigators hypothesize that individuals who receive the 6-month behavioral intervention will demonstrate an increase in physical activity behavior that will last throughout a 6-month follow up compared with participants in the control condition. The investigators further hypothesize that individuals in the behavioral intervention will demonstrate better walking mobility and cognitive function, reduced fatigue, depression, anxiety, and pain, and improved quality of life compared to the control condition. The investigators hypothesize that the behavioral intervention will increase physical activity through positive changes in self-efficacy, outcome expectations, goal setting, and impediments as social-cognitive determinants.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

eHealth-Based Behavioral Intervention for Increasing Physical Activity in Persons With Multiple Sclerosis: Fidelity Protocol for a Randomized Controlled Trial.
Silveira SL, McCroskey J, Wingo BC, Motl RW. · · 2019 · cited 8× · PMID 30821692 · DOI 10.2196/12319
Impact of Usual-Care Physiotherapy on Physical Activity and Self-Efficacy in People With Multiple Sclerosis: An Observational Longitudinal Study.
Torchio A, Fusari G, Cattaneo D, Grosso C, et al · · 2025 · cited 1× · PMID 40357254 · DOI 10.7224/1537-2073.2024-043

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03490240 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 22 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03490240.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing